Overview

26 Week Efficacy, Safety and Tolerability Study of Indacaterol in Patients With Chronic Obstructive Pulmonary Disease (COPD)

Status:
Completed

Trial end date:
2008-08-01

Target enrollment:

Participant gender:

Summary

Stage 1 of the study is designed to provide data about the risk-benefit of 4 dose regimens of indacaterol (75, 150, 300 & 600 µg o.d.) in order to select two doses to carry forward into study Stage 2. Study Stage 2 will provide pivotal confirmation of efficacy, safety, and tolerability of the selected indacaterol doses in patients with COPD

Phase:

Phase 2/Phase 3

Details

Lead Sponsor:

Novartis

Treatments:

Formoterol Fumarate
Tiotropium Bromide